Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.
Read more details at: http://www.bigmarketresearch.com/global-diabetic-retinopathy-2015-2019-market
This results in inflammation of tissue and blurry vision.
Analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market.
The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
• F. Hoffmann-La Roche
• Regeneron Pharmaceuticals...